Indonesia pharmaceuticals market still facing difficult conditions, despite regulatory overhaul

Despite the overhaul of Indonesia's regulatory system, its pharmaceutical sector remains a difficult position. Inadequate patent laws, uncertain government pricing policy and strong domestic capacity are largely to blame, notes a new report from Business Monitor International.

The foreign presence is low as a result, although regional harmonization and an improvement in business conditions will stimulate growth. Some multinationals have local plants, while others import through distributors. Indonesia has problems with transparency, corruption and red tape.

Govt moves to curb corruption